期刊文献+

乳腺癌新辅助治疗患者乳腺内病灶定位标记夹放置和取出的影响因素 被引量:6

暂未订购
导出
摘要 目的分析影响乳腺内病灶Marker放置和取出的影像学因素。方法选择我科2018年1月-2019年2月收治的乳腺癌行新辅助治疗且乳腺病灶内放置标记夹并最终接受手术治疗的患者,根据其影像学资料及标记夹放置和取出的手术记录,比较单独及联合应用超声、X线摄影及磁共振对标记夹的放置、识别和取出的成功率的影响。结果共11例患者入组,新辅助治疗开始前乳腺内病灶在超声、X线和磁共振检查上的检出率分别为100.0%(11/11)、72.7%(8/11)和100.0%(11/11),组间无统计学差异(P>0.05);治疗过程中,超声、X线和磁共振至少有1次识别出标记夹的检出率为0.0%(0/11)、100.0%(11/11)和45.5%(5/11),各组间均有统计学差异(P<0.05);1例在术中仅凭超声检出标记夹并导丝定位(仅凭超声定位成功率9.1%);5例拟行保乳手术者在通过X线立体定位植入导丝(X线定位成功率为100.0%);所有标本离体后X线下证实标记夹包含在标本内。结论乳腺癌新辅助治疗乳腺病灶内标记夹放置选用超声引导下穿刺成功率高,时机在第2周期治疗开始前为宜,治疗后肿瘤接近或达到临床完全缓解且拟行保乳手术者,可优先选用X线引导定位标记夹。
出处 《解放军预防医学杂志》 CAS 2019年第11期10-11,共2页 Journal of Preventive Medicine of Chinese People's Liberation Army
基金 北京市卫生系统高层次卫生技术人才项目(No.2013-2-032)
  • 相关文献

参考文献3

二级参考文献25

  • 1Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res, 1992, 52 ( 8 ) : 2127- 2137.
  • 2Bear HD, Aderson S, Smith RE,et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 2006, 24( 13): 2019-202%
  • 3Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy : prognostic significance and survival. Breast, 2003, 12(5) : 320-327.
  • 4Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol, 2007, 25(28) : 4414-4422.
  • 5Kuerer HM,Newman LA,Smith TL,et al.Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy[J].J Clin Oncol,1999,17(2):460-469.
  • 6Chollet P,Amat S,Cure H,et al.Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer[J].Br J Cancer,2002,86(7)1041-1046.
  • 7Sahoo S,Lester SC.Pathology of breast carcinomas after neoadjuvant chemotherapy:an overview with recommendations on specimen processing and reporting[J].Arch Pathol Lab Med,2009,133(4):633-642.
  • 8Pinder SE,Provenzano E,Earl H,et al.Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy[J].Histopathology,2007,50(4):409-417.
  • 9Rabban J.The new edition(7th)AJCC staging system for breast cancer.A summary of key changes[EB/OL],(2010-06)[2015-02-09].http://labmed.ucsf.edu/uploads/210/101_new_ajcc_ staging_of_breast_cancer_what_has_changed.pdf.
  • 10Edge S,Byrd D,Compton C,et al.AJCC cancer staging manual[M].New York:Springer,2010.

共引文献134

同被引文献51

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部